



# Allergy-Immunology Enrollment Form

Fax: 909-284-9140

Phone: 909-266-0016

**Urgent Request**

Rep: \_\_\_\_\_

## PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name \_\_\_\_\_  
Address \_\_\_\_\_  
Address 2 \_\_\_\_\_  
City, State, Zip \_\_\_\_\_  
Home Phone \_\_\_\_\_ Mobile Phone \_\_\_\_\_  
DOB \_\_\_\_\_ Last Four of SS \_\_\_\_\_ Gender \_\_\_\_\_  
Language Preference \_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber Name \_\_\_\_\_  
DEA \_\_\_\_\_  
NPI \_\_\_\_\_  
Address \_\_\_\_\_  
City, State, Zip \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Contact Person \_\_\_\_\_

## Clinical Diagnosis: please fax or email relevant clinical notes, labs, tests, and previous medical history to expedite prior authorization

**Diagnosis** - Please include diagnosis name with ICD-10 code Additional information Therapy  New  Reauthorization  Restart

L20.9 Atopic Dermatitis  J45.50 Severe persistent asthma uncomplicated  L50.1 chronic idiopathic urticaria

Other Diagnosis: ICD-10 Code \_\_\_\_\_  
Description \_\_\_\_\_  
Date of Diagnosis \_\_\_\_\_  
Estimated length of therapy \_\_\_\_\_

Weight \_\_\_\_\_ kg/lbs. Height \_\_\_\_\_ cm/in

Allergies \_\_\_\_\_ Lab Data \_\_\_\_\_ Prior Therapies \_\_\_\_\_

Concomitant Medications \_\_\_\_\_ Additional Comments \_\_\_\_\_

## PRESCRIPTION INFORMATION

Medication	Dose/Strength	Directions	Quantity	Refills
<input type="checkbox"/> Adbry	<input type="checkbox"/> 150mg/ml PFS	<input type="checkbox"/> Inject 600mg SQ followed by 300mg SQ every 2 weeks (Initial) <input type="checkbox"/> Inject 300mg SQ every 2 weeks (maintenance) <input type="checkbox"/> Inject 300 mg SQ every 4 weeks for patients below 100kg who achieve clear skin after 16 weeks	<input type="checkbox"/> 28 days	
<input type="checkbox"/> Cibinqo	<input type="checkbox"/> 50mg tablets <input type="checkbox"/> 100mg tablets <input type="checkbox"/> 200mg tablets	<input type="checkbox"/> Take 1 tablet by mouth once daily	<input type="checkbox"/> 30 tabs	
<input type="checkbox"/> Dupixent	<input type="checkbox"/> 200mg/2ml PFS <input type="checkbox"/> 200mg/2ml Pens <input type="checkbox"/> 300mg/2ml PFS <input type="checkbox"/> 300mg/2ml Pens	<input type="checkbox"/> Inject 400mg SQ followed by 400mg SQ every 2 weeks (Initial) <input type="checkbox"/> Inject 200mg SQ every 2 weeks (maintenance) <input type="checkbox"/> Inject 600mg SQ followed by 300mg SQ every 2 weeks (Initial) <input type="checkbox"/> Inject 300mg SQ every 2 weeks (maintenance)	<input type="checkbox"/> 28 days	
<input type="checkbox"/> Eucrisa	<input type="checkbox"/> 2% ointment	<input type="checkbox"/> Apply a thin layer to affected area(s) 2 times daily	<input type="checkbox"/> 60 gm <input type="checkbox"/> 100 gm	
<input type="checkbox"/> Fasenra	<input type="checkbox"/> 30mg Vial	<input type="checkbox"/> Inject 30mg every 4 weeks for the first 3 doses (Initial) <input type="checkbox"/> Inject 30mg every 8 weeks (maintenance)		
<input type="checkbox"/> Nucala	<input type="checkbox"/> 100mg Vial	<input type="checkbox"/> Inject 100mg SQ once every 4 weeks into the upper arm, thigh or abdomen		
<input type="checkbox"/> Opzelura	<input type="checkbox"/> 1.5% cream	<input type="checkbox"/> Apply a thin layer to affected area(s) 2 times daily	<input type="checkbox"/> 60 gm	
<input type="checkbox"/> Xolair	<input type="checkbox"/> 150mg Vial			
<input type="checkbox"/> Other				

Ship to:  Patient  Office  Other \_\_\_\_\_ Date: \_\_\_\_\_ Need by Date \_\_\_\_\_

**\* Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s) and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorizations forms and the receipt and submission of patient tab values and other patient data, in the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize the pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Product Substitution permitted  Dispense as Written

Prescriber's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

CONFIDENTIALITY STATEMENT: This communication is intended for use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.